Brief: Timber Pharmaceuticals Receives European Orphan Drug Designation For TMB-001
24/02/2023 13:05
Feb 24 (Reuters) - Timber Pharmaceuticals Inc TMBR.A :
* TIMBER PHARMACEUTICALS RECEIVES EUROPEAN ORPHAN DRUG
DESIGNATION
FOR TMB-001 IN X-LINKED RECESSIVE ICHTHYOSIS
Source text for Eikon: ID:nGNX7TYlp4
Further company coverage: TMBR.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trex Wind-Down
See all newsBrief: NYSE American To Suspend Trading Immediately In Timber Pharma
Brief: Timber Pharmaceuticals Receives Court Approval Of All “First Day” Motions To Support Business
Brief: NYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals
Brief: Timber Pharmaceuticals Says Prior To Filing Of Chapter 11 Case, Debtors Entered Into A "Stalking Horse" Asset Purchase Agreement
Brief: Timber Pharmaceuticals Inc Files For Voluntary Chapter 11 Bankruptcy - Court Filing